Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) PT at $92.43

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fourteen research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $92.43.

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. decreased their target price on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating on the stock in a research report on Thursday, November 21st. Canaccord Genuity Group reaffirmed a "buy" rating and set a $121.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. Wells Fargo & Company raised their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a report on Friday, December 20th. Royal Bank of Canada reissued an "outperform" rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Finally, Piper Sandler boosted their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an "overweight" rating in a report on Monday, January 13th.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 11,727 shares of the business's stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the sale, the chief executive officer now owns 2,183,985 shares in the company, valued at $92,229,686.55. The trade was a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 5.80% of the company's stock.

Institutional Trading of Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 493 shares during the last quarter. Human Investing LLC purchased a new position in Ultragenyx Pharmaceutical during the 4th quarter worth $42,000. True Wealth Design LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth $43,000. Values First Advisors Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at about $56,000. Finally, Van ECK Associates Corp lifted its position in shares of Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 273 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Trading Up 0.9 %

Ultragenyx Pharmaceutical stock traded up $0.41 during trading hours on Monday, reaching $45.78. 761,639 shares of the stock were exchanged, compared to its average volume of 948,135. The stock has a 50 day moving average of $44.09 and a two-hundred day moving average of $49.61. Ultragenyx Pharmaceutical has a twelve month low of $37.02 and a twelve month high of $60.37. The company has a market cap of $4.23 billion, a P/E ratio of -7.08 and a beta of 0.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm had revenue of $139.49 million during the quarter, compared to analysts' expectations of $135.28 million. During the same period in the prior year, the company earned ($2.23) earnings per share. The company's quarterly revenue was up 42.3% on a year-over-year basis. On average, analysts expect that Ultragenyx Pharmaceutical will post -6.13 earnings per share for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.